Anemia Market: By Disease Type (Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia, and Others), By Route of Administration (Oral and Injectable), By Product Type (Biologic and Non-Biologic), By End User (Hospital and Self-Administered) and By Geography

Anemia Market was valued at USD 7,832.8 million in 2023 and is anticipated to grow at a CAGR of 7.3% over 2024-2030. The anemia treatment market refers to the segment of the healthcare industry that focuses on developing and providing therapies, medications, and other interventions for the treatment of anemia. Anemia is a medical condition characterized by a deficiency in red blood cells or hemoglobin, which can lead to reduced oxygen-carrying capacity in the blood. This can result in symptoms such as fatigue, weakness, dizziness, and shortness of breath. The treatment of anemia aims to address the underlying cause of the condition and/or boost the production of red blood cells to restore normal hemoglobin levels.

The anemia treatment market includes various types of treatments, such as Iron supplements, Vitamin B12 supplements, Folate supplements, Erythropoiesis-stimulating agents (ESAs), and Blood transfusions to name a few. The market for anemia treatment is influenced by factors such as the prevalence of anemia, advancements in medical research and technology, healthcare infrastructure, and government healthcare policies. For instance, according to the World Health Organization, 30% (539 million) of non-pregnant women and 37% (32 million) of pregnant women aged 15–49 years were affected by anemia in 2019. Pharmaceutical companies, biotechnology firms, and medical device manufacturers are major players in this market, developing and marketing various treatments to meet the medical needs of patients with anemia. Moreover, Pharmaceutical companies develop and market drugs targeting anemia. For instance, Pharmacosmos launched Monoferric (Ferric Derisomaltose) for the treatment of iron deficiency anemia in adults.

Anemia Market Key Developments:

• In February 2023, GlaxoSmithKline (GSK) received FDA Approval for its Jesduvroq (Daprodustat) indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least four months.
• In November 2022, Sanofi received approval from the European Commission (EC) for Enjaymo (sutimlimab) for the treatment of hemolytic anemia in adult patients with cold agglutinin disease (CAD), a rare, serious, and chronic autoimmune hemolytic anemia, where the body’s immune system mistakenly attacks healthy red blood cells and causes their rupture, known as hemolysis.
• In July 2021, Sandoz launched the generic version of Ferumoxytol, an intravenous medication used to treat iron deficiency anemia (IDA) in the United States.